Impact of FDA black box advisory on antipsychotic medication use
about
Concerns about quetiapineDifferential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeCaregiver and care recipient characteristics as predictors of psychotropic medication use in community-dwelling dementia patients.Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warningsDiffusion of antipsychotics in the US And French markets, 1998-2008Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior.Different black box warning labeling for same-class drugs.Use of atypical antipsychotics in nursing homes and pharmaceutical marketing.Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness.Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategiesPsychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia.A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents.Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series studyRegional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare ExpendituresDosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box WarningChanges in physician antipsychotic prescribing preferences, 2002-2007.Identification and management of in-hospital drug-induced delirium in older patients.Delays in psychiatric drug development in Japan.Can major systematic reviews influence practice patterns? A case study of episiotomy trends.Atypical antipsychotic-induced metabolic disturbances in the elderly.Methodological gaps in the assessment of risk minimization interventions: a systematic review.Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.Assessing approaches and barriers to reduce antipsychotic drug use in Florida nursing homes.Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.Prescribing pattern of antipsychotic drugs during the years 1996-2010: a population-based database study in Europe with a focus on torsadogenic drugs.Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia.New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents.The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.Trends, correlates, and disease patterns of antipsychotic use among elderly persons in Taiwan.Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis.Persistence of racial disparities in prescription of first-generation antipsychotics in the USA.Impact of FDA Black Box Warning on Psychotropic Drug Use in Noninstitutionalized Elderly Patients Diagnosed With Dementia: A Retrospective Study.Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates.Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy.
P2860
Q26773288-664FD2CB-47BC-48B0-A93C-DA468DD2DDC8Q28534696-F7A7985E-3DBA-45B3-9B6A-1F3BA6802CA9Q28535299-F62A471A-DB37-4209-BE95-67E0CCB480BCQ30275696-258E787E-CD87-4939-B671-4CB8B52E8C45Q33888723-37E5AB5B-2866-4615-95F5-28E4716365AEQ33915286-E3D3C2B1-5CAC-40E9-9704-2126C23C2D18Q34245595-B6872230-3D1B-49BB-9A36-32E27DD2A17EQ34506252-8CC6D497-E6F1-4846-BA26-A649F379B398Q34636572-54C56919-85EE-4FF3-84E9-322CFD78D609Q35007039-7671F778-BC80-414B-B965-B564CBDF8D46Q35095380-87EAA81D-443F-4DD4-B72B-D583BC68CAFCQ35217862-FF6AE974-EA18-4D6D-8EDB-86705D4E4EA3Q35523924-4CB64A59-EE3F-4E27-B8B6-27E1FF9CD0D5Q35593200-A243CAB9-80A2-4009-AEB2-573DAC365D3CQ35813455-CFC11CF6-EE09-4521-9E9E-872553904349Q35928690-D0AD0993-B53D-495D-B27A-389C951C376BQ37185836-BA375FC3-73C2-4F0D-851E-77A739E7D03BQ37251173-8AC608AC-F9FB-442B-A173-5CBA0C171421Q37275848-48463819-4E08-4E70-AF73-64CEEED5CCBEQ37626797-02D9A357-3A43-4783-8B94-D162CBF0F23DQ37931232-6864A58C-3ECC-4CD3-A357-D2071BE15C83Q37948093-39FF6B8B-D687-4729-9B2A-D66341ADAC65Q38114317-AC6591E6-9E38-4AEB-B938-335430A6463FQ38183274-E591EA42-406A-41AA-A168-068E2A3EB03AQ38195003-3B45097A-3AD6-4902-9922-C8660EEA2A9BQ38214498-7D197E52-E5B0-4744-8B16-E095F4D063A0Q38244187-A5C3EC9D-C9E8-4904-8F44-BBD84E9CE088Q38391397-5A88FE1D-AD1B-474D-B2E4-C47108DB42C5Q38408656-BBF3D221-D416-4E52-81F1-79BBE1238C94Q38764962-1BD16D03-D17B-4943-BF40-F6A450E33A13Q39529503-796418E4-0B4F-46D6-92AB-5D0376197C1AQ39595929-8D55F7F9-9981-4C57-8973-A94DAD84CBCAQ40211664-E41C7E7A-512A-46AF-819F-5EC077510A09Q40525160-FBE0E905-704F-4DD1-93B1-A9B1FD63BA8BQ40778551-9E536A41-5320-4735-8B16-629795F56DEBQ41008329-05D59698-B7E0-4577-8598-98F61EEAE243Q41682303-4A0ED078-1B08-4F1C-8A29-0CFF4BF5F4AFQ41889038-E5A6CDD8-D429-4798-96AB-D48CEAEDA5DDQ43413416-24E5AFE6-F524-42ED-AB5F-048A2C74725FQ44169182-E10A2A28-84D3-46F8-8953-83877169F2BF
P2860
Impact of FDA black box advisory on antipsychotic medication use
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of FDA black box advisory on antipsychotic medication use
@ast
Impact of FDA black box advisory on antipsychotic medication use
@en
Impact of FDA black box advisory on antipsychotic medication use
@nl
type
label
Impact of FDA black box advisory on antipsychotic medication use
@ast
Impact of FDA black box advisory on antipsychotic medication use
@en
Impact of FDA black box advisory on antipsychotic medication use
@nl
prefLabel
Impact of FDA black box advisory on antipsychotic medication use
@ast
Impact of FDA black box advisory on antipsychotic medication use
@en
Impact of FDA black box advisory on antipsychotic medication use
@nl
P2093
P2860
P1476
Impact of FDA black box advisory on antipsychotic medication use
@en
P2093
Atonu Rabbani
E Ray Dorsey
G Caleb Alexander
Sarah A Gallagher
P2860
P304
P356
10.1001/ARCHINTERNMED.2009.456
P407
P50
P577
2010-01-01T00:00:00Z